Clinical Trials Logo

Filter by:
NCT ID: NCT00365430 Completed - Pressure Ulcer Clinical Trials

SAFE or SORRY? Patient Safety Study of the Prevention of Adverse Patient Outcomes

Start date: September 2006
Phase: N/A
Study type: Interventional

The aim of SAFE or SORRY? is to develop and test an evidence based inpatient safety program for the prevention of three frequently occuring adverse events: pressure ulcers, urinary tract infections and falls.

NCT ID: NCT00365170 Completed - Diabetes Clinical Trials

Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes

Start date: September 2002
Phase: Phase 4
Study type: Interventional

This trial was conducted in Europe, Middle East, North America and South America. The aim of this trial was to compare the use of an intensified insulin treatment with insulin aspart (NovoRapid®) versus human insulin (Actrapid®) in pregnancy.

NCT ID: NCT00364351 Completed - Clinical trials for Non Small Cell Lung Cancer

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

Start date: August 2006
Phase: Phase 3
Study type: Interventional

To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib

NCT ID: NCT00363896 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Start date: August 2006
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.

NCT ID: NCT00363415 Completed - Clinical trials for Small Cell Lung Cancer

Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer

Start date: August 2006
Phase: Phase 3
Study type: Interventional

This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus carboplatin. It is anticipated that pemetrexed plus carboplatin will offer similar survival benefits as compared to etoposide plus carboplatin.

NCT ID: NCT00363350 Completed - Sjogren's Syndrome Clinical Trials

Rituximab Treatment in Sjogren's Syndrome

Start date: August 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an evaluation of the effect of rituximab compared to placebo in combination with steroids on salivary flow and serological and clinical parameters in patients with primary SS.

NCT ID: NCT00363259 Completed - Hepatitis C Clinical Trials

Pegintron Induction Therapy in HCV Non-Responders

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the sustained virological response rate at 24 weeks after the end of experimental treatment (induction and 72 weeks) to that of standard 48 weeks treatment with PEG-inteferon alfa-2b and ribavirin in patients with chronic hepatitis C previous unresponsive to interferon alfa monotherapy or interferon alfa/ribavirin combination therapy.

NCT ID: NCT00363155 Completed - Clinical trials for Hepatitis B, Chronic

KRN7000 in Chronic Hepatitis B

Start date: March 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to determine the safety, tolerability and effectiveness of KRN7000 for chronic hepatitis B infection.

NCT ID: NCT00363051 Completed - Clinical trials for Pancreatic Neoplasms

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Start date: June 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study was to assess the efficacy and safety of everolimus in the treatment of advanced pancreatic neuroendocrine tumor (NET) not responsive to cytotoxic chemotherapy. All patients were treated with everolimus until either tumor progression was documented using a standard criteria that measures tumor size called Response Evaluation Criteria in Solid tumors (RECIST), or until unacceptable toxicity occurred, or until the patient or investigator requested discontinuation of treatment.

NCT ID: NCT00362960 Completed - Clinical trials for Type 2 Diabetes Mellitus

Olmesartan Medoxomil and Diabetic Nephropathy

Start date: May 2003
Phase: Phase 3
Study type: Interventional

Evaluation of several olmesartan dosages compared to losartan on proteinuria, renal function and inflammatory markers in patients with diabetic nephropathy